Skip to main content

Table 3 The 10-year non-relapse mortality (NRM) and rejection rate in the study population

From: The effect of bone marrow-derived mesenchymal stem cell co-transplantation with hematopoietic stem cells on liver fibrosis alleviation and survival in patients with class III β-thalassemia major

Groups Rejection rate P value Non-relapse mortality (NRM) P value
10 years 10 years
Mesenchymal group Yes 14.46% (7.89–22.93%) 0.88 22.02% (13.69–31.59%) 0.222
No 15.52% (9.87–22.34%) 31.88% (22.66–41.47%)
Sex-matched Mismatched 18.52% (11.66–26.61%) 0.08 31.20% (20.90–42.01%) 0.756
Matched 10.23% (5.21–17.23%) 26.74% (18.35–35.85%)
ABO-mismatched Mismatched 18.32% (10.78–27.43%) 0.236 30.13% (20.32–40.53%) 0.543
Matched 12.53% (7.48–18.94%) 27.48% (18.50–37.21%)
Source of HSCT PB 13.68% (8.45–20.17%) 0.404 32.12% (23.46–41.09%) 0.109
BM 17.39% (10.01–26.46%) 20.68% (12.32–30.55%)
Acute GvHD Yes 15.95% (12.42–21.77%) 0.452 37.47% (28.06–46.85%) 0.256
No 22.86% (15.73–30.80%) 29.31% (21.10–39.21%)
Chronic GvHD Yes 16.82% (12.46–25.31%) 0.249 26.77% (16.58–38.02%) 0.349
No 24.32% (17.44–31.83%) 27.70% (20.27–35.60%)
  1. TRM transplant-related mortality, GvHD graft-versus-host disease, BM bone marrow, PB peripheral blood